Obesity and metabolic syndrome are significant global health issues, with current public health messages predominately focused on altering dietary and physical activity behaviors. Resveratrol is a polyphenol (stilbenoid) commonly found in grapes, and human trials to date have shown conflicting and limited beneficial effects with respect to health. The aim of this study was to determine the effect of resveratrol supplementation on reducing body weight and modifying associated inflammatory markers.
Methods:
A systematic review was undertaken following the PRISMA guidelines and using five indexed databases (OVID MEDLINE, Cochrane Library, Web of Science, SCOPUS, and CINAHL). A search strategy was formulated to select randomized, double-blind, placebo-controlled human trials investigating the effects of resveratrol supplementation on obesity or overweight, including body weight, metabolic and inflammatory markers.
Results:
Five thousand five hundred sixty-nine studies published from 1990 to November 2015 were identified, with only nine papers meeting the inclusion criteria. The studies involved 208 participants (aged 49.2 ± 8.3 years) and utilized a substantial range of resveratrol doses (75–3000 mg/day). Study durations were a minimum of 2 weeks (14–90 days). Seven studies indicated no significant change in body mass index or body weight (P > 0.05), and three studies showed no improvements in fat mass, fat volume, or abdominal fat distribution (P > 0.05). Four studies included measurements of inflammatory markers, with three of these finding resveratrol supplementation to have a significant positive effect (P > 0.05).
Conclusion:
Based on the included studies, there is currently insufficient evidence to support the recommendation of resveratrol supplements in management of obesity. However, there were significant but not entirely consistent anti-inflammatory effects after resveratrol supplementation in overweight and obese individuals.
Get full access to this article
View all access options for this article.
References
1.
PeetersA, MamunAA, BonneuxL, et al.Obesity in adulthood and its consequences for life expectancy: A life-table analysis. Ann Intern Med, 2003; 138:24.
2.
MalnickSDH, KnoblerH. The medical complications of obesity. QJM, 2006; 99:565–579.
3.
SinghPN, ArthurKN, OrlichMJ, et al.Global epidemiology of obesity, vegetarian dietary patterns, and noncommunicable disease in Asian Indians. Am J Clin Nutr, 2014; 100:359.
4.
VucenikI, StainsJP. Obesity and cancer risk: Evidence, mechanisms, and recommendations. Ann N Y Acad Sci, 2012; 1271:37–43.
5.
WHO. Global status report on noncommunicable diseases 2014. 2014. Accessed at http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua=1 on 2015. Accessed June23, 2015.
6.
MaesM, BerkM, GoehlerL, et al.Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med, 2012; 10:66.
7.
TrujilloME, SchererPE. Adipose tissue-derived factors: Impact on health and disease. Endocr Rev, 2006; 27:762–778.
8.
TchernofA, DespresJP. Pathophysiology of human visceral obesity: An update. Physiol Rev, 2013; 93:359–404.
9.
CastoldiA, Naffah de SouzaC, CamaraNO, et al.The macrophage switch in obesity development. Front Immunol, 2015; 6:637.
10.
KrabbeKS, ReichenbergA, YirmiyaR, et al.Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun, 2005; 19:453–460.
11.
NaumovskiN. Bioactive Composition of plants and plant foods. In: ScarlettCJ, VuongQV (eds). Plant Bioactive Compounds for Pancreatic Cancer Prevention and Treatment. New York: Nova Publishers; 2015:322.
12.
van der SpuyWJ, PretoriusE. Is the use of resveratrol in the treatment and prevention of obesity premature?. Nutr Res Rev, 2009; 22:111–117.
13.
WangS, Moustaid-MoussaN, ChenL, et al.Novel insights of dietary polyphenols and obesity. Nutr Biochem, 2014; 25:1–18.
14.
AlberdiG, RodríguezVM, MirandaJ, et al.Changes in white adipose tissue metabolism induced by resveratrol in rats. Nutr Metab (Lond), 2011; 8:29.
15.
Gómez-ZoritaS, Fernández-QuintelaA, LasaA, et al.Effects of resveratrol on obesity-related inflammation markers in adipose tissue of genetically obese rats. Nutrition, 2013; 29:1374.
BargerJL, KayoT, VannJM, et al.A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One, 2008; 3:e2264.
18.
LamYY, PetersonCM. Ravussin E, Resveratrol vs. calorie restriction: Data from rodents to humans. Exp Gerontol, 2013; 48:1018.
19.
BaurJA, PearsonKJ, PriceNL, et al.Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006; 444:337–342.
20.
ShangJ, ChenLL, XiaoFX, et al.Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin, 2008; 29:698–706.
21.
AndradeJM, FradeAC, GuimaraesJB, et al.Resveratrol increases brown adipose tissue thermogenesis markers by increasing SIRT1 and energy expenditure and decreasing fat accumulation in adipose tissue of mice fed a standard diet. Eur J Nutr, 2014; 53:1503–1510.
22.
VangO, AhmadN, BaileCA, et al.What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One, 2011; 6:e19881.
23.
ManachC, ScalbertA, MorandC, et al.Polyphenols: Food sources and bioavailability. Am J Clin Nutr, 2004; 79:727.
24.
MilitaruC, DonoiuI, CraciunA, et al.Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: Effects on lipid profiles, inflammation markers, and quality of life. Nutrition, 2013; 29:178–183.
25.
PoulsenMM, VestergaardPF, ClasenBF, et al.High-dose resveratrol supplementation in obese men an investigator- initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes, 2013; 62:1186–1195.
26.
Méndez-Del VillarM, González-OrtizM, Martínez-AbundisE, et al.Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord, 2014; 12:497–501.
27.
YoshinoJ, ConteC, FontanaL, et al.Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab, 2012; 16:658–664.
28.
LiuK, ZhouR, WangB, et al.Effect of resveratrol on glucose control and insulin sensitivity: A meta-analysis of 11 randomized controlled trials. Am J Clin Nutr, 2014; 99:1510–1519.
29.
HausenblasHA, SchouldaJA, SmoligaJM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus—systematic review and meta-analysis. Mol Nutr Food Res, 2015; 59:147–159.
30.
SahebkarA, SerbanC, UrsoniuS, et al.Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors—Results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol, 2015; 189:47–55.
31.
MoherD, LiberatiA, TetzlaffJ, et al.Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ, 2009; 339:b2535.
32.
ZorzelaL, LokeYK, IoannidisJP, et al.PRISMA harms checklist: Improving harms reporting in systematic reviews. BMJ, 2016; 352:i157.
33.
HigginsJPT, AltmanDG, JonathanAC. Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT, SallyG (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. Available from www.cochrane-handbook.org
34.
WongRHX, BerryNM, CoatesAM, et al.Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J Hypertens, 2013; 31:1819–1827.
35.
DashS, XiaoC, MorgantiniC, et al.High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler Thromb Vasc Biol, 2013; 33:2895–2901.
36.
TimmersS, KoningsE, BiletL, et al.Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab, 2011; 14:612–622.
37.
ChachayVS, MacdonaldGA, MartinJH, et al.Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2014; 12:2092–2103.
38.
FaghihzadehF, AdibiP, RafieiR, et al.Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res, 2014; 34:837–843.
39.
MovahedA, NabipourI, Lieben LouisX, et al.Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med, 2013; 2013:851267.
40.
GohKP, LeeHY, LauDP, et al.Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int J Sport Nutr Exerc Metab, 2014; 24:2–13.
41.
World Health Organization. Obesity and overweight. 2014. Accessed at www.who.int/mediacentre/factsheets/fs311/en/ on August30, 2014.
42.
WillisLM, Shukitt-HaleB, JosephJA. Modulation of cognition and behavior in aged animals: Role for antioxidant- and essential fatty acid-rich plant foods. Am J Clin Nutr, 2009; 89:1602S.
43.
HurselR, Westerterp-PlantengaMS. Catechin- and caffeine-rich teas for control of body weight in humans. Am J Clin Nutr, 2013; 98(6 Suppl):1682S.
44.
de LigtM, TimmersS, SchrauwenP. Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?. Biochim Biophys Acta, 2015; 1852:1137–1144.
45.
SmoligaJM, BaurJA, HausenblasHA. Resveratrol and health—A comprehensive review of human clinical trials. Mol Nutr Food Res, 2011; 55:1129–1141.
46.
SzkudelskiT, SzkudelskaK. Resveratrol and diabetes: From animal to human studies. Biochim Biophys Acta, 2015; 1852:1145–1154.
47.
NaumovskiN, BladesBL, RoachPD. Food inhibits the oral bioavailability of the major green tea antioxidant epigallocatechin gallate in humans. Antioxidants (Basel), 2015; 4:373–393.
48.
HeebollS, ThomsenKL, PedersenSB, et al.Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol, 2014; 6:188–198.
49.
BujandaL, HijonaE, LarzabalM, et al.Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol, 2008; 8:40–40.
50.
LagougeM, ArgmannC, Gerhart-HinesZ, et al.Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006; 127:1109.
51.
Dal-PanA, BlancS, AujardF. Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol, 2010; 10:11.
52.
DandonaP, AljadaA, BandyopadhyayA. Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol, 2004; 25:4–7.
53.
OlholmJ, PaulsenSK, CullbergKB, et al.Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes, 2010; 34:1546–1553.
